Evidence map›Paper›PMID 38344715›Full record

ArticleKidney international reports2024

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A

Akihiko Koshino, Brendon L Neuen, Megumi Oshima, Tadashi Toyama, Akinori Hara, Clare Arnott, Bruce Neal, Meg Jardine, Sunil V Badve, Kenneth W Mahaffey and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 5 countries.

Akihiko KoshinoDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Brendon L NeuenThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Megumi OshimaDepartment of Nephrology and Rheumatology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
Tadashi ToyamaDepartment of Nephrology and Rheumatology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
Akinori HaraDepartment of Nephrology and Rheumatology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
Clare ArnottThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Bruce NealThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Meg JardineThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Sunil V BadveThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California, USA.
Carol PollockKolling Institute of Medical Research, Sydney Medical School, University of Sydney, New South Wales, Australia.
Michael K HansenJanssen Research and Development, LLC, Spring House, Pennsylvania, USA.
Takashi WadaDepartment of Nephrology and Rheumatology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Kanazawa University · JPUNSW Sydney · AUThe University of Sydney · AUCenter for Clinical Research (United States) · USJanssen (United States) · USRoyal Prince Alfred Hospital · AUUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Autoantibodies to erythropoietin receptor (anti-EPOR antibodies) have been identified in patients with various kidney diseases. However, data in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) is limited. We assessed the prevalence of anti-EPOR antibodies and their association with clinical outcomes in this population. Methods: The CREDENCE randomized patients with T2D and CKD to canagliflozin or placebo. Serum anti-EPOR antibodies, the exposure of interest, were measured using enzyme-linked immunosorbent assay. The primary outcome was doubling of serum creatinine, end-stage kidney disease, or death from kidney or cardiovascular (CV) causes. Secondary outcomes included CV and all-cause mortality. Multivariable Cox-regression models estimated associations between anti-EPOR antibodies and outcomes. The effects of canagliflozin on hemoglobin and hematocrit, stratified by the presence of anti-EPOR antibodies were assessed with a repeated measures mixed effects model. Results: Of 2600 participants with available biosamples, 191 (7.3%) were positive for anti-EPOR antibodies. Higher baseline anti-EPOR antibodies were associated with increased risk of primary outcome (hazard ratio [HR] per 1-SD increase = 1.12, 95% confidence interval [CI] = 1.01-1.24, Conclusion: In patients with T2D and CKD, anti-EPOR antibodies were associated with the composite kidney and CV outcome, as well as CV and all-cause mortality. Canagliflozin increased hemoglobin and hematocrit regardless of anti-EPOR antibodies.

Indexed as

anemiabiomarkercardiovascularkidneymortalitySGLT2 inhibitor

Identifiers

PMID38344715
PMCPMC10850998
OpenAlexW4389235624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.